New biotech fund for Belgian companies!

June 8, 2015 News BioVox

Désiré Collen launched a new biotech fund, Fund+. The founder of Thrombogenics collected money from Urbain Vandeurzen, AB InBev billionaire Arnaud de Pret and government funds. The ambition of Désiré Collen is to gather 100 million euro to invest in Belgian biotech companies: “Thusfar only 18,5 million is available, but agreements for 60 million euros have been made. Also, 20 million euros have been promised within one month. This means that 100 million euros is close. We keep the number of investors deliberately limited and we are working with big-ticket investments of 2 to 10 million euros.” Collen, who is currently the chairman of the fund, hopes to make a real difference.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter